The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA
Open accessAbstract
RNA-guided endonucleases (RGENs) derived from the CRISPR/Cas system represent an efficient tool for genome editing. RGENs consist of two components: Cas9 protein and guide RNA. Plasmid-mediated delivery of these components into cells can result in uncontrolled integration of the plasmid sequence into the host genome, and unwanted immune responses and potential safety problems that can be caused by the bacterial sequences. Furthermore, this delivery method requires transfection tools. Here we show that simple treatment with cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs leads to endogenous gene disruptions in human cell lines. The Cas9 protein was conjugated to CPP via a thioether bond, whereas the guide RNA was complexed with CPP, forming condensed, positively charged nanoparticles. Simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA, leads to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections, resulting in the generation of clones containing RGEN-induced mutations. Our CPP-mediated RGEN delivery process provides a plasmid-free and additional transfection reagent-free method to use this tool with reduced off-target effects. We envision that our method will facilitate RGEN-directed genome editing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“RNP electroporation exhibits higher on-target editing efficiency and lower off-target mutations than the other delivery methods”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Ramakrishna et al., 2014
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A powerful advantage of the CRISPR/Cas9 system is the ability to target any ∼23-bp sequence that contains a PAM motif on either strand of DNA.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ramakrishna et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“cell-penetrating peptides (CPP), conjugated with Cas9 and complexed with gRNA enabled efficient gene silencing in human cell lines and disease models featuring fewer off-target effects when compared to plasmid transfection [153,154].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [153]
Experimental — accuracy not yet measuredIn the citing paper
“Ramakrishna et al. demonstrated that conjugating Cas9 and sgRNA with cell-penetrating peptides (CPPs) enhanced intracellular delivery efficiency because of the membrane-disturbed properties of CPPs.[227]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [227]
In the citing paper
“Some work with CPPs and CRISPR/Cas9 was accomplished as early as 2014 by Ramakrishna et al. (2014), who showed separate delivery of CPP–Cas9 and CPP–sgRNA to multiple human cell lines.”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Ramakrishna et al., 2014
In the citing paper
“Ramakrishna et al. developed cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs for gene disruptions of CCR5 locus in human cell lines, including HEK293T, HeLa, NCCIT (a human pluripotent embryonal carcinoma cell line), human dermal fibroblasts and human embryonic stem cells.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [96]
In the citing paper
“Cell-penetrate-peptide-mediated delivery was reported to achieve higher on-to off-target activity ratio compared with plasmid-mediated delivery.53”
From CRISPR-Cas9: a new and promising player in gene therapy (2015) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 3×
“responses (Hemmi et al. 2000; Wagner 2001) caused by bacterial sequences, and safety problems if the antibiotic-resistance gene is taken up by pathogenic bacteria.”
BackgroundInfluentialDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,471
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 653
Shen, Y., Cohen, J. L., Nicoloro, S. M. C., Kelly, M., Yenilmez, B., Henriques, F. D. S., Tsagkaraki, E., Edwards, Y. J. K., Hu, X., Friedline, R. H., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004554 · Cited by 61
Recent developments in intracellular protein delivery
Zhang, Y., Røise, J. J., Lee, K., Li, J., & Murthy, N. (2018) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2018.02.009 · Cited by 62
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
Caneva, A. D., Porro, F., Bortolussi, G., Sola, R., Lisjak, M., Barzel, A., Giacca, M., Kay, M. A., Vlahoviček, K., Zentilin, L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128863 · Cited by 61
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 63
Dewari, P. S., Southgate, B., McCarten, K., Monogarov, G., O’Duibhir, E., Quinn, N., Tyrer, A., Leitner, M.-C., Plumb, C., Kalantzaki, M., et al. (2018) · eLife · doi:10.7554/elife.35069 · Cited by 63
Nanobiomaterial vectors for improving gene editing and gene therapy
Hu, S. W., Ding, T., Tang, H., Guo, H., Cui, W., & Shu, Y. (2023) · Materials Today · doi:10.1016/j.mattod.2023.04.011 · Cited by 58
Hu, J. H., Davis, K. M., & Liu, D. R. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.12.009 · Cited by 61
Practical guidance for the implementation of the CRISPR genome editing tool in filamentous fungi
Kwon, M., Schütze, T., Spohner, S., Haefner, S., & Meyer, V. (2019) · Fungal Biology and Biotechnology · doi:10.1186/s40694-019-0079-4 · Cited by 49
Zhang, D., Liu, L., Jin, S., Tota, E. M., Li, Z., Piao, X., Zhang, X., Fu, X., & Devaraj, N. K. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c12166 · Cited by 57
Lin, Y., Wilk, U., Pöhmerer, J., Hörterer, E., Höhn, M., Luo, X., Mai, H., Wagner, E., & Lächelt, U. (2022) · Small · doi:10.1002/smll.202205318 · Cited by 58
Engineering self-deliverable ribonucleoproteins for genome editing in the brain
Chen, K., Stahl, E. C., Kang, M. H., Xu, B., Allen, R., Trinidad, M. I., & Doudna, J. A. (2024) · Nature Communications · doi:10.1038/s41467-024-45998-2 · Cited by 61
Intelligent nanotherapeutic strategies for the delivery of CRISPR system
Chen, C., Zhong, W., Du, S., Li, Y., Zeng, Y., Liu, K., Yang, J., Guan, X., & Han, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.013 · Cited by 54
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 59
Ma, X., Chen, C., Veevers, J., Zhou, X., Ross, R. S., Feng, W., & Chen, J. (2017) · Scientific Reports · doi:10.1038/srep42244 · Cited by 53
Chemical engineering of CRISPR–Cas systems for therapeutic application
Barber, H. M., Pater, A. A., Gagnon, K. T., Damha, M. J., & O’Reilly, D. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01086-0 · Cited by 57
Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field
He, Z., Men, K., Qin, Z., Yang, Y., Xu, T., & Wei, Y.-Q. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9033-0 · Cited by 55
Delivery of Cas9/sgRNA Ribonucleoprotein Complexes via Hydroxystearyl Oligoamino Amides
Kuhn, J., Lin, Y., Levačić, A. K., Danaf, N. A., Peng, L., Höhn, M., Lamb, D. C., Wagner, E., & Lächelt, U. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00853 · Cited by 54
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors
Shalaby, K. E., Aouida, M., & El‐Agnaf, O. M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197353 · Cited by 55
Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption
Ha, J. S., Lee, J., Jeong, J., Kim, H., Byun, J., Kim, S. A., Lee, H. J., Chung, H. S., Lee, J. B., & Ahn, D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.007 · Cited by 52
Self-citationAdvances in peptide-mediated cytosolic delivery of proteins
Sánchez‐Navarro, M. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.003 · Cited by 55
Recent Advances in CRISPR/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells
Lotfi, M., Rad, D. M., Mashhadi, S., Ashouri, A., Mojarrad, M., Mozaffari‐Jovin, S., Farrokhi, S., Hashemi, M., Lotfi, M., Warkiani, M. E., et al. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10585-3 · Cited by 54
Delivery systems of CRISPR/Cas9-based cancer gene therapy
Biagioni, A., Laurenzana, A., Margheri, F., Chillà, A., Fibbi, G., & Rosso, M. D. (2018) · Journal of Biological Engineering · doi:10.1186/s13036-018-0127-2 · Cited by 52
Lee, S., Kim, Y.-Y., & Ahn, H. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120793 · Cited by 50
Self-citationScaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing
Chin, J. S., Chooi, W. H., Wang, H., Ong, W., Leong, K. W., & Chew, S. Y. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.020 · Cited by 51
Cruz, L. J., van Dijk, T., Vepris, O., Li, T. M. W. Y., Schomann, T., Baldazzi, F., Kurita, R., Nakamura, Y., Grosveld, F. G., Philipsen, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120580 · Cited by 51
Han, X., Liu, Z., Ma, Y., Zhang, K., & Qin, L. (2017) · Advanced Biosystems · doi:10.1002/adbi.201600007 · Cited by 50
The potential for targeted rewriting of epigenetic marks in COPD as a new therapeutic approach
Wu, D., Song, J., Bartel, S., Krauss‐Etschmann, S., Rots, M. G., & Hylkema, M. N. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.007 · Cited by 50
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
Nanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 51
Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy
Godbout, K., & Tremblay, J. P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102129 · Cited by 51
Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing
Hanson, B., Wood, M. J. A., & Roberts, T. C. (2021) · RNA Biology · doi:10.1080/15476286.2021.1874161 · Cited by 49
Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes
Jain, P., Lo, J. H.-J., Rananaware, S. R., Downing, M. A., Panda, A., Tai, M., Raghavan, S., Fleming, H. E., & Bhatia, S. N. (2019) · Nanoscale · doi:10.1039/c9nr01786k · Cited by 47
Development of delivery strategies for CRISPR‐Cas9 genome editing
Liu, Q., Yang, J., Xing, Y., Zhao, Y., & Liu, Y. (2023) · BMEMat · doi:10.1002/bmm2.12025 · Cited by 47
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1
Hernández, G., Ramı́rez, M. J., Minguillón, J., Quiles, P., Ponce, G. R. D. G., Aza‐Carmona, M., Bogliolo, M., Pujol, R. M., Prados‐Carvajal, R., Fernández‐Rodríguez, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03433-3 · Cited by 49
Furuhata, Y., Sakai, A., Murakami, T., Morikawa, M., Nakamura, C., Yoshizumi, T., Fujikura, U., Nishida, K., & Kato, Y. (2019) · Scientific Reports · doi:10.1038/s41598-018-38119-9 · Cited by 47
Kuivanen, J., Korja, V., Holmström, S., & Richard, P. (2019) · Fungal Biology and Biotechnology · doi:10.1186/s40694-019-0066-9 · Cited by 46
CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool
Sahel, D. K., Mittal, A., & Chitkara, D. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257287 · Cited by 47
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Self-citationTyagi, A., Kaushal, K., Chandrasekaran, A. P., Sarodaya, N., Das, S., Park, C., Hong, S., Kim, K.-S., & Ramakrishna, S. (2022) · Theranostics · doi:10.7150/thno.72826 · Cited by 44
Self-citationBehzadipour, Y., & Hemmati, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116910 · Cited by 45
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
Farboud, B., Jarvis, E., Roth, T. L., Shin, J. J., Corn, J. E., Marson, A., Meyer, B. J., Patel, N. H., & Hochstrasser, M. L. (2018) · Journal of Visualized Experiments · doi:10.3791/57350 · Cited by 52
Kang, S., Jeon, S., Kim, S., Chang, Y. K., & Kim, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78968-x · Cited by 44
Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
Gustafsson, O., Rädler, J., Roudi, S., Lehto, T., Hällbrink, M., Lehto, T., Gupta, D., Andaloussi, S. E., & Nordin, J. Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060878 · Cited by 44
Comprehensive Protocols for CRISPR/Cas9‐based Gene Editing in Human Pluripotent Stem Cells
Santos, D. P., Kiskinis, E., Eggan, K. C., & Merkle, F. T. (2016) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.15 · Cited by 45
Impact of the Endosomal Escape Activity of Cell-Penetrating Peptides on the Endocytic Pathway
Kondow-McConaghy, H. M., Muthukrishnan, N., Erazo‐Oliveras, A., Najjar, K., Juliano, R. L., & Pellois, J. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00319 · Cited by 46
Lee, H.-M., Ren, J., Tran, K. M., Jeon, B.-M., Park, W.-U., Kim, H., Lee, K. E., Oh, Y., Choi, M., Kim, D. S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01726-w · Cited by 43
Self-citationSattar, M. N., Iqbal, Z., Al-Khayri, J. M., & Jain, S. M. (2021) · Plants · doi:10.3390/plants10071347 · Cited by 45
Yin, J., Hou, S., Wang, Q., Bao, L., Liu, D., Yue, Y., Yao, W., & Gao, X. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00022 · Cited by 41
Genetic and Covalent Protein Modification Strategies to Facilitate Intracellular Delivery
Horn, J. M., & Obermeyer, A. C. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00745 · Cited by 39
Alariqi, M., Ramadan, M., Yu, L., Hui, F., Hussain, A., Zhou, X., Yu, Y., Zhang, X., & Jin, S. (2025) · Advanced Science · doi:10.1002/advs.202416331 · Cited by 42
CRISPR‐Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies
Wen, W., Yuan, Z., Ma, S., Jiang, X., & Yuan, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29626 · Cited by 41
Wang, H., Ma, J.-L., Yang, Y., Song, Y., Wu, J., Qin, Y., Zhao, X., Wang, J., Zou, L., Wu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8682 · Cited by 40
Advanced editing of the nuclear and plastid genomes in plants
Piatek, A., Lenaghan, S. C., & Stewart, C. N. (2018) · Plant Science · doi:10.1016/j.plantsci.2018.02.025 · Cited by 40
Lee, N., Shin, J., Park, J. H., Lee, G. M., Cho, S., & Cho, B. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00249 · Cited by 41
Paving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 43
Shen, J.-Y., Zhao, Q., & He, Q. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00099 · Cited by 39
Mahato, R. K., Bhattacharya, S., Khullar, N., Sidhu, I. S., Reddy, P. H., Bhatti, G. K., & Bhatti, J. S. (2023) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2023.12.003 · Cited by 40
Ilahibaks, N. F., Kluiver, T. A., de Jong, O. G., de Jager, S. C. A., Schiffelers, R. M., Vader, P., Peng, W. C., Lei, Z., & Sluijter, J. P. G. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12389 · Cited by 42
Membrane Oxidation Enables the Cytosolic Entry of Polyarginine Cell-penetrating Peptides
Wang, T., Sun, Y., Muthukrishnan, N., Erazo‐Oliveras, A., Najjar, K., & Pellois, J. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711564 · Cited by 39
A Tale of Two Moieties: Rapidly Evolving CRISPR/Cas-Based Genome Editing
Yang, L. C., & Chen, J. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.06.003 · Cited by 38
Huang, X., Li, A., Xu, P., Yu, Y., Li, S., Hu, L., & Feng, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01952-w · Cited by 43
CRISPR-Cap: multiplexed double-stranded DNA enrichment based on the CRISPR system
Lee, J., Lim, H., Jang, H. S., Hwang, B., Lee, J. H., Cho, J., Lee, J. H., & Bang, D. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky820 · Cited by 39
On the expression of recombinant Cas9 protein in E. coli BL21(DE3) and BL21(DE3) Rosetta strains
Carmignotto, G. P., & Azzoni, A. R. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.09.012 · Cited by 38
Öktem, M., de Jong, O. G., & Mastrobattista, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102500 · Cited by 36
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 37
Advances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 37
Jo, Y.-I., Suresh, B., Kim, S., & Ramakrishna, S. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.003 · Cited by 36
Self-citationKim, K. H., Choi, B. K., Kim, Y. H., Han, C., Oh, H. S., Lee, D. G., & Kwon, B. S. (2016) · Autophagy · doi:10.1080/15548627.2016.1196314 · Cited by 39
Unlocking Genome Editing: Advances and Obstacles in CRISPR/Cas Delivery Technologies
Kaupbayeva, B., Tsoy, A., Safarova, Y., Nurmagambetova, A., Murata, H., Matyjaszewski, K. A., & Askarova, S. (2024) · Journal of Functional Biomaterials · doi:10.3390/jfb15110324 · Cited by 40
Recent advances in poly(amino acids), polypeptides, and their derivatives in drug delivery
Yuan, H., Jiang, M., Fang, H., & Tian, H. (2024) · Nanoscale · doi:10.1039/d4nr04481a · Cited by 38
Taylor, J., & Woodcock, S. A. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115590069 · Cited by 35
Re-engineered RNA-Guided FokI-Nucleases for Improved Genome Editing in Human Cells
Havlicek, S., Shen, Y., Alpagu, Y., Bruntraeger, M., Zufir, N. B. M., Phuah, Z. Y., Fu, Z., Dunn, N. R., & Stanton, L. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.11.007 · Cited by 33
CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells
Riggan, L., Hildreth, A. D., Rolot, M., Wong, Y. Y., Satyadi, W., Sun, R., Huerta, C., & O’Sullivan, T. E. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107651 · Cited by 37
Strategies for High-Efficiency Mutation Using the CRISPR/Cas System
Feng, S., Wang, Z., Li, A., Xie, X., Liu, J., Li, S., Li, Y., Wang, B., Hu, L., Yang, L., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.803252 · Cited by 40
Intracellular delivery of fluorescent protein into viable wheat microspores using cationic peptides
Bilichak, A., Luu, J., & Eudes, F. (2015) · Frontiers in Plant Science · doi:10.3389/fpls.2015.00666 · Cited by 34
Merlin, J. P. J., & Abrahamse, H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117516 · Cited by 35
Use of genome-editing tools to treat sickle cell disease
Tasan, I., Jain, S., & Zhao, H. (2016) · Human Genetics · doi:10.1007/s00439-016-1688-0 · Cited by 36
Cell-penetrating peptides and their utility in genome function modifications (Review)
Gagat, M., Zielińska, W., & Grzanka, A. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3172 · Cited by 36
Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications
Shtykalova, S., Deviatkin, D., Freund, S., Egorova, A., & Kiselev, A. (2023) · Life · doi:10.3390/life13040903 · Cited by 43
Lohia, A., Sahel, D. K., Salman, M., Singh, V., Mariappan, I., Mittal, A., & Chitkara, D. (2022) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2022.02.001 · Cited by 33
Glemzaite, M., Balciunaite, E., Karvelis, T., Gasiūnas, G., Grusyte, M. M., Alzbutas, G., Jurcyte, A., Anderson, E. M., Maksimova, E. M., Smith, A. J., et al. (2015) · RNA Biology · doi:10.1080/15476286.2015.1017209 · Cited by 33
A genome editing primer for the hematologist
Hoban, M. D., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2016-01-678151 · Cited by 32
Synthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 34
A traceless linker for aliphatic amines that rapidly and quantitatively fragments after reduction
He, M., Li, J., Han, H., Borges, C. A., Neiman, G., Røise, J. J., Hadaczek, P., Mendonsa, R., Holm, V. R., Wilson, R. C., et al. (2020) · Chemical Science · doi:10.1039/d0sc00929f · Cited by 33
Kaitsuka, T., & Tomizawa, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125986 · Cited by 34
Chandrasekaran, A. P., Kaushal, K., Park, C., Kim, K.-S., & Ramakrishna, S. (2021) · Theranostics · doi:10.7150/thno.63806 · Cited by 33
Self-citationCRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering
Glinšek, K., Bozovičar, K., & Bratkovič, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098144 · Cited by 35
Application of the genome editing tool CRISPR/Cas9 in non-human primates.
Luo, X., Li, M., & Su, B. (2016) · Europe PMC (PubMed Central) · doi:10.13918/j.issn.2095-8137.2016.4.214 · Cited by 32
The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing
Vicente, M. M., Chaves‐Ferreira, M., Jorge, J. M. P., Proença, J. T., & Barreto, V. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718466 · Cited by 31
Haq, S., Sarodaya, N., Karapurkar, J. K., Suresh, B., Jo, J. K., Singh, V., Bae, Y. S., Kim, K.-S., & Ramakrishna, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.032 · Cited by 33
Self-citationD-repeat in theXISTgene is required for X chromosome inactivation
Lv, Q., Yuan, L., Song, Y., Sui, T., Li, Z., & Lai, L. (2016) · RNA Biology · doi:10.1080/15476286.2015.1137420 · Cited by 31
Mérien, A., Tahraoui‐Bories, J., Cailleret, M., Dupont, J.-B., Leteur, C., Polentes, J., Carteron, A., Polvèche, H., Concordet, J., Pinset, C., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab218 · Cited by 33
Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms
Tian, S., Liu, Y., Appleton, E., Wang, H., Church, G. M., & Dong, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110476 · Cited by 30
Gene Therapy for Inherited Retinal Degeneration
Arbabi, A., Liu, A., & Ameri, H. (2019) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2018.0087 · Cited by 30
Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer
Li, Y., Li, C., Yan, J., Liao, Y., Qin, C., Wang, L., Huang, Y., Yang, C. H., Wang, J., Ding, X., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122573 · Cited by 30
Yuan, B., Keller, N. P., Oakley, B. R., Stajich, J., & Wang, C. C. C. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00456 · Cited by 30
Gonzalez, V. G., Grunenberger, A., Nicoud, O., Czuba, E., Vollaire, J., Josserand, V., Guével, X. L., Desai, N., Coll, J., Divita, G., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.008 · Cited by 29
Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 29
Using CRISPR to enhance T cell effector function for therapeutic applications
Heeren, J. J. F. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100049 · Cited by 31
Metadata
- Authors
- Ramakrishna, S., Kwaku Dad, A.-B., Beloor, J., Gopalappa, R., Lee, S.-K., & Kim, H.
- Affiliations
- Hanyang University (KR)
- Venue
- Genome Research
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-04-02
- Volume
- 24
- Issue
- 6
- Pages
- 1020-1027
- ISSN
- 1088-9051 (ISSN-L)
- PMC
- PMC4032848
- OpenAlex
- W2103609218
- Cited by
- 655
- References
- 45
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 41 · 2023: 46 · 2022: 64 · 2021: 76 · 2020: 66 · 2019: 60 · 2018: 77 · 2017: 60 · 2016: 56 · 2015: 50 · 2014: 11
- Type
- posted content
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Genome Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Research Foundation
- Hanyang University
- Yonsei University
- Korea Basic Science Institute
- National Research Foundation of Korea (2013M3A9B4076544, 2011‐0019357)
- Korea Advanced Institute of Science and Technology
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, cell-penetrating peptides, gene disruption, genome editing, guide RNA delivery, off-target mutations, embryonic stem cells, human cell lines
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Humans, Transfection, Genome, Human, Mutagenesis, Site-Directed, RNA Editing, RNA, Guide, Kinetoplastida, Cell Line, Tumor, Nanoparticles, HEK293 Cells, Cell-Penetrating Peptides, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
